Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 44 от 240

Набира участници Фаза 3

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

Amyotrophic Lateral Sclerosis

The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is: Does pridopidine slow disease progression of ALS? Researchers will compare pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works to treat ALS. Participants will: Take pridopidine or a placebo by mouth every day for 48 weeks. Afterwards, all participants will take pridopidine for another 48 weeks. Visit the clinic once every 1-3 months for checkups and tests

Начало: 01.02.2026 Край: 01.03.2029 Възраст: 18–80 г.

Canada, United States Prilenia NCT07322003

Набира участници

Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy

Peripheral Neuropathy Due to Chemotherapy Peripheral Neuropathy Neurotoxicity Syndromes Neuropathy

This study aims to evaluate nerve excitability in participants with cisplatin-induced peripheral neuropathy (cis-PN) using threshold tracking nerve conduction studies (TTNCS). By assessing changes in nerve excitability parameters, the study seeks to enhance understanding of the pathophysiology of cis-PN and identify early markers of neurotoxicity in participants undergoing cisplatin-based chemotherapy.

Начало: 31.01.2026 Край: 31.12.2028 Възраст: от 18 г.

United States Ka-Wai Ho NCT07095998

Набира участници Фаза 2/3

Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Autosomal Dominant Hypocalcemia Type 1 (ADH1)

The overall objective of this study is to evaluate the pharmacokinetics (PK), efficacy, and safety of encaleret in pediatric participants from birth to 17 years of age with ADH1.

Начало: 30.01.2026 Край: 01.12.2030 Възраст: до 17 г.

United Kingdom, United States Calcilytix Therapeutics, Inc., a BridgeBio company NCT07080385

Набира участници Фаза 1/2

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Advanced/Metastatic Non-Small Cell Lung Cancer Carcinoma, Non-Small Cell Lung Non-Small Cell Lung Cancer

This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery or cured with standard treatments. To join in the study, participants must: * Be 18 years or older * Participants with advanced non-small cell lung cancer (NSCLC), a type of lung cancer that has spread The study will look at: * Whether PF-08634404 is safe to use with other cancer medicines. * What side effects may happen. A side effect is anything the medicine does to your body that is not part of treating your disease. * Whether the combination of PF-08634404 and other cancer medicines can help treat solid tumors. The study has different parts, each testing PF-08634404 with a different cancer medicine: * Part A will test PF-08634404 with a medicine called sigvotatug vedotin. * Part B of the study will look at how well the new medicine PF-08634404 works when used together with another medicine. Participants will receive the study medicines through an intravenous (IV) infusion (injected into the vein) at the study clinic. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.

Начало: 30.01.2026 Край: 23.08.2033 Възраст: от 18 г.

Japan, Puerto Rico, Taiwan +1 Pfizer NCT07227298

Набира участници

Online Pivotal Response Treatment Training in Autism Spectrum Disorder

Autism Spectrum Disorder Autism

This is a research study that will assess the effects of a Pivotal Response Treatment Online Training Course (PRT-O) for training parents of children with Autism Spectrum Disorder (ASD). The study will specifically investigate whether participants can learn to deliver PRT effectively following participation in the Online training.

Начало: 30.01.2026 Край: 30.12.2028 Възраст: 2–5 г.

United States Stanford University NCT06523387

Набира участници

Kinematics and Muscle Activity During the Tennis Serve and Musculoskeletal Characteristics in Tennis Players With Subacromial Pain Syndrome or History of Shoulder Pain

Shoulder Pain

Tennis players often suffer from shoulder pain due to the repetitive high-loaded overhead movements during serving, and subacromial pain syndrome is one of the main types of shoulder pain. Previous shoulder injury has been identified as one of the risk factors for shoulder overuse injuries in overhead sports. No research has explored differences in trunk kinematics and shoulder muscle activities among tennis players with and without subacromial pain syndrome or a history of shoulder pain. Furthermore, limited studies have examined shoulder kinematics during tennis serve and musculoskeletal characteristics in tennis players with subacromial pain syndrome or a history of shoulder pain. Therefore, this study aims to investigate shoulder and trunk kinematics and shoulder muscle activity during the tennis serve and musculoskeletal characteristics in tennis players with subacromial pain syndrome or a history of shoulder pain. This study will recruit sixty tennis players with subacromial pain syndrome, a history of shoulder pain, and healthy players. The electromagnetic tracking system will be applied to collect shoulder and trunk kinematics during the tennis serve, and surface electromyography will be simultaneously used for recording shoulder muscle activities. Moreover, we will collect shoulder and trunk rotational joint range of motion, isometric strength and rate of force development of shoulder internal and external rotation, scapulothoracic and glenohumeral joint control capability, upper quarter Y-balance test performance, and posterior shoulder endurance. This study will compare the difference of these measures in tennis players with subacromial pain syndrome or a history of shoulder pain to healthy players.

Начало: 29.01.2026 Край: 29.01.2027 Възраст: 18–40 г.

Taiwan National Yang Ming Chiao Tung University NCT07543484

Набира участници Фаза 1/2

Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected Individuals

HIV

An Exploratory Multicenter, Open-label, Sequential Cohort Study to Evaluate the Preliminary Efficacy, Safety, and Pharmacokinetic Characteristics of LP-98 for Injection in Antiretroviral Therapy-Naive HIV-Infected Individuals

Начало: 29.01.2026 Край: 25.09.2026 Възраст: 18–65 г.

China Shanxi Kangbao Biological Product Co., Ltd. NCT07433387

Набира участници Фаза 2

SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.

Painful Peripheral Neuropathy Diabetic Peripheral Neuropathic Pain (DPN) Chemotherapy Induced Peripheral Neuropathy (CIPN) Idiopathic Peripheral Neuropathy

The goal of this clinical trial is to determine whether quantitative sensory testing (QST) can be used to classify participants into pain sub-groups and predict who will respond best to certain pain treatments in participants with painful peripheral neuropathy. The analgesic effect is evaluated by measuring pain intensity and Patient Global Impression of Change (PGIC). This study is a 3-period cross-over trial. This means researchers will compare 3 different drugs (pregabalin, duloxetine, and placebo) over a period of 19 weeks. Participants will: * Undergo a quantitative sensory testing (QST) exam. * Provide a blood sample. * Complete questionnaires on the computer. * Take the study drug as instructed.

Начало: 29.01.2026 Край: 01.06.2028 Възраст: 18–80 г.

United States University of Rochester NCT06614322

Набира участници Фаза 3

Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab

Severe Asthma

This study aims to explore the potential for Tezepelumab-treated severe asthmatic patients to effectively and safely reduce their background maintenance medication while maintaining asthma symptom control.

Начало: 28.01.2026 Край: 31.03.2029 Възраст: 12–80 г.

China AstraZeneca NCT07363642

Набира участници Фаза 2

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

Eosinophilic Asthma

This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma. The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.

Начало: 28.01.2026 Край: 01.12.2027 Възраст: 18–75 г.

Serbia, United Kingdom, United States Kymera Therapeutics, Inc. NCT07323654

Набира участници

A Study to Assess the Ability of Stereotactic Radiotherapy to Restore the Efficacy of Immunotherapy in Patients With Metastatic Cancer.

Metastatic Cancer

This study aims at enrolling patients with solid tumors at metastatic stage, considered long responders to immunotherapy (\> 6 months) and displaying disease progression. In this study, the investigator wants to evaluate specific modalities of stereotactic radiotherapy, with 3 sessions, each of 8 Gy, lasting 20 minutes and spaced 72 hours apart (Day 1, Day 4, Day 7). The radiotherapy device itself is not the subject of this study and will be used in accordance with its CE mark and indications. The objective of the study is to assess the ability of stereotactic radiotherapy to restore the lost efficacy of immunotherapy. In particular, the abscopal effect will be assessed, i.e. the action of irradiating a particular target lesion and observing an effect on other distant metastases.

Начало: 27.01.2026 Край: 01.01.2028 Възраст: от 18 г.

France Elsan NCT06363773

Набира участници Фаза 3

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Advanced Endometrial Carcinoma Recurrent Endometrial Carcinoma

This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with stage III, IVA or IVB mismatch repair protein proficient (pMMR) and TP53 mutated endometrial cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has come back after a period of improvement (recurrent). Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Adding bevacizumab to the combination of carboplatin, paclitaxel and pembrolizumab may be more effective than the usual treatment combinations of carboplatin and paclitaxel with or without pembrolizumab in treating patients with advanced or recurrent pMMR and TP53 mutated endometrial cancer.

Начало: 27.01.2026 Край: 01.07.2028 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT07198074

Набира участници Фаза 2

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Adenocarcinoma Carcinoma, Pancreatic Ductal

This is a Phase 2, single-arm study to evaluate the safety and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (PDAC).

Начало: 27.01.2026 Край: 01.07.2027 Възраст: от 18 г.

United States Corcept Therapeutics NCT07259317

Набира участници

Effect of Lactiplantibacillus Plantarum LM1001 on Muscle Strength in Older Adults

Age-Related Muscle Weakness

Purpose: This clinical trial aims to evaluate the efficacy and safety of Lactiplantibacillus plantarum LM1001 in improving muscle strength in older adults. The study is designed to investigate its potential effects on muscle strength based on the gut-muscle axis. Methodology: This study is a randomized, double-blind, placebo-controlled, single-center clinical trial. A total of 100 participants will be enrolled and randomly assigned to either the test group (n=50) or the placebo group (n=50). Participants in the test group will receive 500 mg of Lactiplantibacillus plantarum LM1001 (1.0 × 10¹⁰ CFU/day) once daily for 12 weeks, while those in the placebo group will receive a matching placebo. Key Outcome Measures: To evaluate the effects on muscle strength, the following parameters will be assessed at baseline and after the 12-week intervention period: \- Primary Outcome Measures: Changes in isokinetic knee extension and flexion strength. \- Secondary Outcome Measures: Changes in muscle strength-related parameters, including muscle power, skeletal muscle mass (SMM), and skeletal muscle mass index (SMI), as well as physical performance measures such as handgrip strength, Short Physical Performance Battery (SPPB) score, Timed Up and Go (TUG) test, and health-related quality of life assessed by EQ-5D-5L. \- Safety Assessments: Safety will be evaluated based on the incidence of adverse events, serum biochemical parameters, and clinical laboratory test results.

Начало: 27.01.2026 Край: 31.12.2026 Възраст: 50–85 г.

South Korea Lactomason Co., Ltd. NCT07538830

Набира участници

Anifrolumab Malignancy and Serious Infections Study

Systemic Lupus Erythematosus

This is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.

Начало: 26.01.2026 Край: 30.11.2031 Възраст: 18–130 г.

Denmark, France, Germany +1 AstraZeneca NCT07000110

Набира участници Фаза 3

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Obesity Overweight

The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.

Начало: 24.01.2026 Край: 01.11.2028 Възраст: от 18 г.

Argentina, Canada, United States Eli Lilly and Company NCT07357415

Набира участници

Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.

Short Bowel Syndrome (SBS) Intestinal Failure

Eligible patients were randomized into two groups: the GLP-1 group and the control group. The control group received a placebo along with standard care, without any additional GLP-1-based intervention. The GLP-1 group, in addition to standard care, received a subcutaneous injection of a GLP-1 analog (semaglutide injection) strictly according to the drug manufacturer's instructions. The initial dose of semaglutide was 0.25 mg once weekly. Treatment was continued over a 28-days period. Primary and secondary outcomes will be collected.

Начало: 24.01.2026 Край: 31.05.2026 Възраст: 18–80 г.

China Jinling Hospital, China NCT07297238

Набира участници Фаза 2

Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

Bipolar I Disorder

Phase II study for patients with Bipolar 1 Disorder experiencing major depressive episode. Patient eligible for enrollment will be randomized (like flipping a coin) to either active drug (LB-102 or placebo). Treatment is for 6 weeks.

Начало: 23.01.2026 Край: 01.02.2028 Възраст: 18–65 г.

United States LB Pharmaceuticals Inc. NCT07494305

Набира участници Фаза 2

Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia

Tardive Dyskinesia

The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.

Начало: 23.01.2026 Край: 01.03.2027 Възраст: 18–75 г.

United States Neurocrine Biosciences NCT07365462

Набира участници Фаза 3

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).

Начало: 22.01.2026 Край: 01.11.2031 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +4 BeOne Medicines NCT07277231

1 … 42 43 44 45 46 … 240